https://www.selleckchem.com/pr....oducts/i-brd9-gsk602
1 2.0 months) and OS (median 12.9 7.8 months) than the irinotecan group in patients with 0 or 1 of these factors, whereas the irinotecan group showed a significantly longer PFS (median 1.0 1.8 months) and a trend of longer OS (median 3.9 6.1 months) in patients with ⩾2 of these factors. Some clinical and molecular factors were associated with outcomes following nivolumab or irinotecan as the third- or later-line treatment in patients with AGC. These factors must be considered while selecting an optimal treatment option. Some clini
Like
Comment
Share
